Can Kyprolis® (carfilzomib) be administered once a week, rather than twice a week?

 

In this week’s video, Dr. Brian G.M. Durie explains how the ARROW study demonstrated efficacy and low toxicity for weekly dosing of carfilzomib.

BOTTOM LINE:​

Ensure your doctor is aware of the ARROW study in order to consider once-weekly dosing of carfilzomib.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org. 

Give Where Needed Most

$500
$250
$100
$50
other

Learn More

 

We would like to thank:

Amgen, Astellas Pharma, Binding Site, Bristol-Myers Squibb, Celgene, Diplomat Pharmacy, Genentech, Hoffmann-La Roche, Janssen, Karyopharm Therapeutics, Merck, Novartis, Oncopeptides, Sanofi-Genzyme, Takeda Oncology